| Autor: |
Abdelgawad N; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Tshavhungwe MP; Division of Neurosurgery, Department of Surgery, University of Cape Town, Cape Town, South Africa., Rohlwink U; Division of Neurosurgery, Department of Surgery, University of Cape Town, Cape Town, South Africa.; Neuroscience Institute, University of Cape Town, Cape Town, South Africa., McIlleron H; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.; Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Abdelwahab MT; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Wiesner L; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Castel S; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Steele C; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Enslin JN; Division of Neurosurgery, Department of Surgery, University of Cape Town, Cape Town, South Africa., Thango NS; Division of Neurosurgery, Department of Surgery, University of Cape Town, Cape Town, South Africa., Denti P; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Figaji A; Division of Neurosurgery, Department of Surgery, University of Cape Town, Cape Town, South Africa.; Neuroscience Institute, University of Cape Town, Cape Town, South Africa. |
| Abstrakt: |
Limited knowledge is available on the pharmacokinetics of rifampicin in children with tuberculous meningitis (TBM) and its penetration into brain tissue, which is the site of infection. In this analysis, we characterize the distribution of rifampicin in cerebrospinal fluid (CSF), lumbar (LCSF) and ventricular (VCSF), and brain extracellular fluid (ECF). Children with TBM were included in this pharmacokinetic analysis. Sparse plasma, LCSF, and VCSF samples were collected opportunistically, as clinically indicated. Brain ECF was sampled using microdialysis (MD). Rifampicin was quantified with liquid chromatography with tandem mass spectrometry in all samples, and 25-desacetyl rifampicin in the plasma samples. The data were interpreted with nonlinear mixed-effects modeling, with the CSF and brain ECF modeled as "effect compartments." Data were available from 61 children, with median (min-max) age of 2 (0.3 to 10) years and weight of 11.0 (4.8 to 49.0) kg. A one-compartment model for parent and metabolite with first-order absorption and elimination via saturable hepatic clearance described the data well. Allometric scaling, maturation, and auto-induction of clearance were included. The pseudopartition coefficient between plasma and LCSF/VCSF was ~5%, while the value for ECF was only ~0.5%, possibly reflecting low recovery of rifampicin using MD. The equilibration half-life between plasma and LCSF/VCSF was ~4 h and between plasma and ECF ~2 h. Our study confirms previous reports showing that rifampicin concentrations in the LCSF are lower than in plasma and provides novel knowledge about rifampicin in the VCSF and the brain tissue. Despite MD being semiquantitative because the relative recovery cannot be quantified, our study presents a proof-of-concept that rifampicin reaches the brain tissue and that MD is an attractive technique to study site-of-disease pharmacokinetics in TBM. |
